July 13 (Reuters) - The U.S. FDA on Monday ‌approved an at-home starting dose of Eisai's and Biogen's Alzheimer's ‌drug, allowing some patients to begin therapy with injections administered by ...

Eisai and Biogen won approval from the Food and Drug Administration for an injection of their Leqembi Iqlik drug as an initiation dose to treat early Alzheimer's disease. The companies said Monday the ...

STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental ...

The US Food and Drug Administration has approved Biogen and Eisai's Alzheimer's drug, clearing way for at home treatment of the disease with injections administered by patients ‌or a caregiver, the ...

Shares of Biogen BIIB rose nearly 5% yesterday after the company announced that the FDA approved a subcutaneous (SC) autoinjector version of Leqembi as an initiation dosing option for the treatment of ...

The FDA has approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai Inc.), an amyloid-beta-directed antibody indicated for treating adult patients ...

Once-weekly 500 mg subcutaneous initiation is delivered by autoinjector as two 250 mg injections, allowing self- or caregiver administration at home rather than clinic-based IV starts. FDA acceptance ...

Please provide your email address to receive an email when new articles are posted on . Patients can use subcutaneous lecanemab during the 18-month initiation period. Symptoms were stable for 72.5% of ...

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...